Iwona Schymalli's guest is prof. Lidia Gil from the Department and Clinic of Hematology and Bone Marrow Transplantation at the Medical University.
MRS
Prof. Lidia Gil: Unmet needs in hematology
Published Feb. 9, 2022 11:02
- The treatment standard for acute myeloid leukemia is changing for the first time in 50 years. In Poland, we still rely on standard chemotherapy, which is the basis for the treatment of acute leukemia, but today we can precisely characterize this disease and use targeted therapies that significantly improve treatment results. Last year, the Ministry of Health made one therapy available to patients, but we are still waiting for the second step. We are waiting for oral targeted therapy. Gliterinib is a drug that is approved for resistant and relapsing forms. Its phenomenon is high efficiency.
- A very important breakthrough is the use of gemtuzumab ozogamicin as an additional drug along with intensive chemotherapy, which significantly improves treatment outcomes.
- The biggest breakthrough that we are particularly lacking in de novo therapy in patients who do not qualify for intensive treatment is the combination of venetoclax and azacitadine. This combination shows surprisingly good results and is well tolerated by the patients.
- In line 1, we use the treatment that works best. The response to this treatment is a prognostic factor. Intensive treatment allows us to control the disease as quickly as possible.
- Patients with aggressive lymphomas await Car-T. As a hematology community, we are prepared to conduct this treatment and there are more and more centers accredited for this treatment.
- In the case of multiple myeloma, there are a number of standards that have been in force in Europe for years, but are not financed in Poland. This applies to simple drugs with which we have had a lot of experience for years, such as lenalidomide, which should be used in the first line in selected patients.
- What we are waiting for the most as an environment is daratumumab in the first line and its subcutaneous form.
Topics
szpiczak / hematologia / hematoonkologia / CAR-T / lidia gil / ostra białaczka szpikowa / Medyczna racja stanu
